Table 2 Prognostic risk factors for POD24 determined in univariate and multivariate logistic regression analysis.

From: Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma

Variables

Univariate

Multivariate

β

S.E

Z

P

OR (95%CI)

β

S.E

Z

P

OR (95%CI)

Histologic grade (IIIa vs. I to II)

2.40

1.14

2.11

0.035

11.00 (1.18 ~ 102.35)

     

CD4 + T cell count < 260/uL

2.93

0.99

2.96

0.003

18.75 (2.68 ~ 130.94)

2.86

0.99

2.88

0.004

17.5 (2.50 ~ 122.50)

LDH elevated

1.22

0.89

1.37

0.170

3.37 (0.59 ~ 19.21)

     

β2-MG elevated

1.27

0.86

1.48

0.139

3.56 (0.66 ~ 19.11)

     

HGB

-0.06

0.03

-2.16

0.031

0.94 (0.89 ~ 0.99)

     

Age > 60

1.06

0.87

1.22

0.224

2.89 (0.52 ~ 16.03)

     

Gender (Male)

-0.56

0.91

-0.62

0.537

0.57 (0.10 ~ 3.38)

     

FLIPI high risk

2.77

1.15

2.41

0.016

16.00 (1.68 ~ 152.01)

     

Stage IV

0.52

0.84

0.63

0.532

1.69 (0.33 ~ 8.73)

     

Abbreviations: POD24, disease progression within 2 years after receiving first-line therapy; OR: Odds Ratio, CI: Confidence Interval; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; HGB, Hemoglobin.

Back to article page